SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of June 24, 2026, SYRE stock price declined to $86.09 with 3,261,849 million shares trading.

SYRE has a beta of 1.64, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.10 to the broad based SPY ETF.

SYRE has a market cap of $7.43 billion. This is considered a Mid Cap stock.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, IWM, XBI, VXF, IBB.

SYRE has outperformed the market in the last year with a price return of +486.4% while the SPY ETF gained +23.4%. SYRE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +101.3% and +12.6%, respectively, while the SPY returned +12.1% and -0.3%, respectively.

SYRE support price is $92.99 and resistance is $101.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.